{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:31:18Z","timestamp":1789072278625,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"Active Biotech"},{"name":"US Department of Defense Prostate Cancer Clinical Trials Consortium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostate"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1002\/pros.23277","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T14:38:24Z","timestamp":1479307104000},"page":"385-395","source":"Crossref","is-referenced-by-count":9,"title":["Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial"],"prefix":"10.1002","volume":"77","author":[{"given":"Andrew J.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Humeniuk","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; Duke University; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Szmulewitz","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Chicago; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Winters","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kephart","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Chicago; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Mundy","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; Duke University; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"George","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology; Departments of Medicine and Surgery; Duke Cancer Institute; Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"10.1002\/pros.23277-BIB0001|pros23277-cit-0001","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1517\/13543784.2010.514262","article-title":"The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer","volume":"19","author":"Isaacs","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1002\/pros.23277-BIB0002|pros23277-cit-0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1756287215603558","article-title":"Tasquinimod in the treatment of castrate-resistant prostate cancer-Current status and future prospects","volume":"8","author":"Mehta","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1002\/pros.23277-BIB0003|pros23277-cit-0003","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pbio.1000097","article-title":"Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides","volume":"7","author":"Bjork","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1002\/pros.23277-BIB0004|pros23277-cit-0004","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J Exp Med"},{"key":"10.1002\/pros.23277-BIB0005|pros23277-cit-0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.yexcr.2005.10.013","article-title":"S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells","volume":"312","author":"Hermani","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1002\/pros.23277-BIB0006|pros23277-cit-0006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"10.1002\/pros.23277-BIB0007|pros23277-cit-0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1476-4598-9-107","article-title":"Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors","volume":"9","author":"Olsson","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1002\/pros.23277-BIB0008|pros23277-cit-0008","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-12-2730","article-title":"Tasquinimod is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment","volume":"73","author":"Isaacs","year":"2013","journal-title":"Cancer Res"},{"key":"10.1002\/pros.23277-BIB0009|pros23277-cit-0009","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/pros.23133","article-title":"Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment","volume":"76","author":"Magnusson","year":"2016","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0010|pros23277-cit-0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/pros.21495","article-title":"Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)","volume":"72","author":"Jennbacken","year":"2012","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0011|pros23277-cit-0011","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.bjc.6605322","article-title":"Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer","volume":"101","author":"Bratt","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1002\/pros.23277-BIB0012|pros23277-cit-0012","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pros.23277-BIB0013|pros23277-cit-0013","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1158\/1078-0432.CCR-13-1581","article-title":"Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer","volume":"19","author":"Armstrong","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pros.23277-BIB0014|pros23277-cit-0014","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/pros.23277-BIB0015|pros23277-cit-0015","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1002\/pros.23277-BIB0016|pros23277-cit-0016","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/pros.20573","article-title":"The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts","volume":"67","author":"Dalrymple","year":"2007","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0017|pros23277-cit-0017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/pros.23277-BIB0018|pros23277-cit-0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1002\/pros.23277-BIB0019|pros23277-cit-0019","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.jchromb.2011.09.013","article-title":"Bioanalysis in clinical development of tasquinimod using liquid chromatography\/tandem mass spectrometry","volume":"879","author":"Hansson","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1002\/pros.23277-BIB0020|pros23277-cit-0020","unstructured":"Sennbro CJ"},{"key":"10.1002\/pros.23277-BIB0021|pros23277-cit-0021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-012-2058-9","article-title":"Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors","volume":"71","author":"Ferron","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pros.23277-BIB0022|pros23277-cit-0022","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pros.23277-BIB0023|pros23277-cit-0023","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/pros.20573","article-title":"The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts","volume":"67","author":"Dalrymple","year":"2007","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0024|pros23277-cit-0024","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/pros.21495","article-title":"Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)","volume":"72","author":"Jennbacken","year":"2012","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0025|pros23277-cit-0025","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J ClinOncol"},{"key":"10.1002\/pros.23277-BIB0026|pros23277-cit-0026","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/pros.21467","article-title":"Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts","volume":"72","author":"Dalrymple","year":"2012","journal-title":"Prostate"},{"key":"10.1002\/pros.23277-BIB0027|pros23277-cit-0027","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pros.23277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:24:31Z","timestamp":1625444671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23277"}},"subtitle":["Tasquinimod and Cabazitaxel in mCRPC"],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/pros.23277","archive":["Portico"],"relation":{},"ISSN":["0270-4137"],"issn-type":[{"value":"0270-4137","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}